<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.cancer.org_research_we-2Dfund-2Dcancer-2Dresearch_apply-2Dresearch-2Dgrant_grant-2Dtypes_rfa-2Drole-2Dhealthcare-2Dinsurance-2Dcancer.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=9o67nLbs0jE6H50Euv5NWLJB5j2bDaApXlfMXPIkqzM&e=" target="_blank">American Cancer Society: Role of Health Policy
and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The American Cancer Society is accepting proposals for research projects with the potential to generate new knowledge of the effects of the United States healthcare system structure and the role of insurance
in both access to and the outcomes of cancer screening, early detection, and treatment services.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">ACS is keenly interested in supporting rapid learning research on the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to facilitators and barriers
to care; unintended consequences; differential experiences and outcomes of patients seeking or receiving care; best practice models for quality care; and economic impact. Awards will not exceed $200,000 per year (direct costs) for up to four years.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 1, 2019 and October 15, 2019.
<span style="color:red">Med-RA deadline to receive draft documents for the April deadline: March 18.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDK-2D18-2D007.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=yIhqa5s3pX97KiLc1_TN0SDVqOdHWgk_CrRWvG-XyrU&e=" target="_blank">Complications of Pediatric Type 1 Diabetes (T1D) - Planning Cooperative Agreements (U34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive
complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and
3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission
of the U34 application.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 11, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: March 28.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.whitehall.org_applying_&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=dqXJ3d1Aos67WmPT1NDDVlhkWlacQ5oNeSiadL9I_cU&e=" target="_blank">Whitehall Foundation Grant Programs: Basic Biological Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">It is the Whitehall Foundation's policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized missions. The
Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex
functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. The Whitehall Foundation does not support research focused primarily on disease(s) unless it will
also provide insights into normal functioning. <b>Research grants</b> are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects
of the proposal as well as on the competence of the applicant. Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded
to investigators who have already received, or expect to receive, substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year.
<b>Grants-in-Aid program</b> is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All
applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant’s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due April 15, 2019 and October 1, 2019.
<span style="color:red">Med-RA deadline to receive draft documents for the April deadline: April 1.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.healtheffects.org_research_funding_rosenblith-2Daward&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=x7iJyT44mixm0LtZTv2yiz3RvIWHw8kgB_EezfWvvWA&e=" target="_blank">Health Effects Institute: Rosenblith New Investigator Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Health Effects Institute (HEI) is a nonprofit corporation chartered in 1980 as an independent research organization to provide high-quality, impartial, and relevant science on the health effects of
air pollution. As part of its mission, HEI established the Walter A. Rosenblith New Investigator Award to provide funding for outstanding investigators who are beginning their independent research careers. By providing financial support for investigators at
an early point in their careers, the institute hopes to encourage highly qualified individuals to undertake research on the health effects of air pollution.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Each award will be up to $150,000 per year, with a maximum of $450,000 over three years. The funds can be used to provide salary support for the investigator and supporting junior personnel as well as
operating costs, including supplies and equipment.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Scientists of any nationality holding a PhD, ScD, MD, DVM, or DrPH degree or equivalent are eligible to apply. At the time of application, the candidate should have two to seven years of research experience
after obtaining the highest degree and must be in an assistant professor or equivalent position in an academic or research institution.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Preliminary applications due April 15, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: April 1.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAA-2D19-2D006.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=Li6PAiJnBQSaSRiGFQ7l9B5WfFQDTqPE9cAxr5i3TdQ&e=" target="_blank">Mechanistic studies on chronic alcohol use and sleep homeostasis (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), encourages Research Project Grant (R01) applications proposing to conduct mechanistic
studies on the relationships between sleep problems and alcohol dependence. A major impediment for recovery from alcohol use disorder (AUD) is the persistent sleep problems during abstinence promoting relapse. The objective of this FOA is to promote research
in animal models and human subjects on the reciprocal relationships between chronic alcohol use and sleep disruptions. The major goal is to understand the underlying mechanisms that will lead to improved treatments for alcohol dependence. NIAAA strongly encourages
collaborative efforts between experts in sleep research and established alcohol investigators to facilitate the development of applications incorporating both areas of research. Projects measuring acute effects of alcohol, circadian changes and observational
studies will not be considered responsive to this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 17, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: April 3.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDK-2D19-2D001.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=oes_BpYFW3_S267SU8nqlI96OQ_ryLPZ60O-jxHDj_0&e=" target="_blank">Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity
Research (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring)
for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing
hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide, RBP4, myostatin, FGF21). The proposed assays should be highly reproducible, easily transferable
to other laboratories, easy to multiplex, and validated in human plasma or serum.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 17, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: April 3.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D100.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=T8oK7F1ZWzuGYWwocHA57TdFaTIu2JOZtMKcq50qO74&e=" target="_blank">Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions
(R34 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of augmented or modified interventions designed to promote sustained improvement in attention-deficit/hyperactivity
disorder (ADHD) symptoms and functional impairments across settings and transitions in children, adolescents, and young adults. An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven,
empirical approach to applying modifications that will have a significant and enduring impact on functioning. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and
potential effectiveness of the approach; to address whether the intervention engages the target mechanism(s) presumed to underlie the intervention effects; and to obtain necessary preliminary data as a pre-requisite to a larger-scale, definitive effectiveness
trial.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 1, 2019 and November 15, 2019.
<span style="color:red">Med-RA deadline to receive draft documents for the May deadline: April 17.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Secondary Data Analysis to Examine Long-Term and/or Potential Cross-Over Effects of Prevention Interventions: What are the Benefits for Preventing Mental Health Disorders? (R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D110.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=x8UFVM0K6moFkcbJcaqjDhi53SUpXBmsYfdyGx8-xYM&e=" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing data sets from preventive intervention trials implemented early in life to: 1) examine
risk and protective factors relevant to later mental health outcomes in childhood, adolescence and young adulthood; and 2) determine whether preventive interventions delivered earlier in life have long-term effects, and/or cross-over effects (e.g., unanticipated
beneficial effects), on important mental health outcomes, including serious mental illness (e.g., depression, anxiety, suicide ideation and behaviors, psychosis behaviors).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 2, 2019 and January 2, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for the May deadline: April 18.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D011.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=q1jlRBMJeaXe1Ti_cB20fyUXXoe0FbXUfcOtKpZqrIc&e=" target="_blank">Computational Models of Immunity (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective
immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation
to validate and improve the utility and robustness of the computational models. Another goal of this FOA is to make the computational models and data developed under this initiative readily available to the broader research community for further refinement
or direct use in biological experimentation. This program will also support workshops and symposia to foster the use of computational models of immunity by the broader research community.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 10, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: May 28.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><span style="font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></a></b><span style="font-family:Palatino;color:black">.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>